Biotechnology Canada-headquartered Generex Biotechnology Corporation (OTCQB:GNBT) yesterday announced that its wholly-owned subsidiary, Antigen Express has entered into a license and research agreement with Shenzhen BioScien Pharmaceuticals to develop and commercialize the Antigen Express AE37 immunotherapeutic vaccine for prostate cancer in China (including Taiwan, Hong Kong, and Macau). 8 December 2017